Effects of micronized progesterone added to non-oral estradiol on lipids and cardiovascular risk factors in early postmenopause: a clinical trial

Table 3 Anthropometric and metabolic variables and markers of endothelial function (n = 86)

	Baseline	E2	E2+P	P
Total-c (mg/dL)	216 ± 31^a	207 ± 30^b	203 ± 32^b	< 0.01
HDL-c (mg/dL)	63 ± 16	61 ± 15	61 ± 15	0.06
LDL-c (mg/dL)	129 ± 29^a	123 ± 29^a,b	119 ± 28^b	< 0.01
Triglycerides (mg/dL)	120 ± 53	115 ± 51	111 ± 53	0.2
Fast glucose (mg/dL)	91 ± 11	91 ± 8	92 ± 11	0.2
2h glucose (mg/dL)	103 ± 27	108 ± 36	105 ± 36	0.2
Insulin (μU/mL)	6.9 (3.9-9.7)	6.2 (2.8 -8.8)	6.9 (3.8 -9.1)	0.2
hsCRP (mg/L)	1.51 (0.38-2.9)	1.64 (0.4-3)	1.19 (0.3-2.1)	0.1

Values expressed as median and interquartile range or mean ± SD. P = two-way analysis of variance with repeated measures (non parametric variables were log-converted for statistical analysis and reconverted for presentation in table format).
Different superscript letters indicate statistical difference with Bonferroni multiple-comparison correction test (α < 5%).
Baseline: before hormone therapy; E2: estradiol only; E2+P estradiol + micronized progesterone.
HDL-c high-density lipoprotein cholesterol, hsCRP high-sensitivity C-reactive protein test, LDL-c low-density lipoprotein cholesterol, Total-c total lipoprotein cholesterol; 2h glucose: glucose levels 2 hours after 75g oral glucose load.